Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Provided By PR Newswire
Last update: Oct 28, 2025
Achieved Total Net Product Sales of $790 Million Representing 28% Year-Over-Year Growth
INGREZZA® (valbenazine) Third-Quarter 2025 Net Product Sales of $687 Million Representing 12% Year-Over-Year Growth
Read more at prnewswire.com155.02
+0.03 (+0.02%)
Find more stocks in the Stock Screener
NBIX Latest News and Analysis
6 days ago - By: Chartmill
